Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.

ABSTRACT:

Background

The primary aim of this randomized neoadjuvant trial in operable, HER2-positive breast cancer, was to determine the efficacy on pathologic complete response (pCR) of substituting lapatinib (L) for trastuzumab (T) or adding L to T, in combination with weekly paclitaxel (WP) following AC. Results on pCR were previously reported. Here, we report data on planned secondary endpoints, recurrence-free interval (RFI) post-surgery, and overall survival (OS).

Methods

All patients received standard AC q3 weeks × 4 cycles followed by WP (80 mg/m²) on days 1, 8, and 15, q28 days × 4 cycles. Concurrently with WP, patients received either T (4 mg/kg load, then 2 mg/kg) weekly until surgery, L (1250 mg) daily until surgery, or weekly T plus L (750 mg) daily until surge

SUBMITTER: Rastogi P 

PROVIDER: S-EPMC11225589 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature